Market Closed -
Japan Exchange
11:30:00 10/05/2024 am IST
5-day change
1st Jan Change
1,152
JPY
+1.68%
-4.64%
+5.59%
KAINOS Laboratories, Inc. announced that it has received ¥435.12 million in funding from Asahi Kasei Pharma Corporation
On May 29, 2019, KAINOS Laboratories, Inc. (JASDAQ:4556) closed the transaction.
KAINOS Laboratories, Inc. announced that it has received ¥250.47 million in funding from Sysmex Corporation
14/22/14
CI
KAINOS Laboratories, Inc. announced that it expects to receive ¥250.47 million in funding from Sysmex Corporation
25/22/25
CI
Tranche Update on KAINOS Laboratories, Inc.'s Equity Buyback Plan announced on November 25, 2021.
26/21/26
CI
KAINOS Laboratories, Inc.'s Equity Buyback announced on November 25, 2021, has closed with 150,000 shares, representing 3.66% for ¥158.1 million.
26/21/26
CI
KAINOS Laboratories, Inc. announces an Equity Buyback for 150,000 shares, for ¥158.1 million.
25/21/25
CI
KAINOS Laboratories, Inc. authorizes a Buyback Plan.
25/21/25
CI
Tranche Update on KAINOS Laboratories, Inc.'s Equity Buyback Plan announced on November 25, 2020.
26/20/26
CI
KAINOS Laboratories, Inc.'s Equity Buyback announced on November 25, 2020, has closed with 88,000 shares, representing 2.02% for ¥90.29 million.
26/20/26
CI
KAINOS Laboratories, Inc. announces an Equity Buyback for 90,000 shares, representing 2.02% for ¥100 million.
25/20/25
CI
KAINOS Laboratories, Inc. authorizes a Buyback Plan.
25/20/25
CI
KAINOS Laboratories, Inc. announced that it has received ¥435.12 million in funding from Asahi Kasei Pharma Corporation
29/19/29
CI
KAINOS Laboratories, Inc. announced that it expects to receive ¥435.12 million in funding from Asahi Kasei Pharma Corporation
13/19/13
CI
Tranche Update on KAINOS Laboratories, Inc.'s Equity Buyback Plan announced on September 25, 2018.
26/18/26
CI
KAINOS Laboratories, Inc.'s Equity Buyback announced on September 25, 2018 has expired with 490,800 shares, representing 11.01% for ¥541.35 million. The company repurchased 490,800 shares from Hitachi Chemical Company, Ltd..
26/18/26
CI
KAINOS Laboratories, Inc. announces an Equity Buyback for 500,000 shares, representing 11.22% for ¥551.5 million.
25/18/25
CI
KAINOS Laboratories, Inc. authorizes a Buyback Plan.
25/18/25
CI
Kainos Laboratories, Inc. announced that it has received ¥105.12 million in funding from Trust & Custody Services Bank, Ltd., Investment Arm.
10/16/10
CI
Kainos Laboratories, Inc. announced that it expects to receive ¥105.12 million in funding from Trust & Custody Services Bank, Ltd., Investment Arm.
25/16/25
CI
Tranche Update on Kainos Laboratories, Inc.'s Equity Buyback Plan announced on August 25, 2015.
26/15/26
CI
Kainos Laboratories, Inc.'s Equity Buyback announced on August 25, 2015, has expired with repurchase of 270,000 shares, representing 6.07% for ¥160.65 million.
26/15/26
CI
Kainos Laboratories, Inc. announces an Equity Buyback for 300,000 shares, representing 6.74% for ¥210 million.
25/15/25
CI
Kainos Laboratories, Inc. authorizes a Buyback Plan.
25/15/25
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
KAINOS Laboratories, Inc. is pricipally engaged in researching, developing, manufacturing and selling clinical diagnostic reagents, including biochemical diagnostic reagents such as renal function related reagents and automatic biochemical analytical reagents, immune serological test reagents such as transfusion-related reagents, allergy-related reagents, cancer marker related reagents, and other reagents.
More about the company
1st Jan change
Capi.
+5.59% 32.88M -1.29% 12.64B -0.47% 8.46B +22.61% 5.27B -2.03% 4.49B -53.56% 3.11B +19.30% 2.87B +33.07% 2.31B -8.42% 2.23B -3.55% 1.89B
Diagnostic & Testing Substances
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
KAINOS LABORATORIES, INC. 
